Objective: The objective of this clinical review is to highlight the otolaryngological symptoms that occur in pregnancy. Where available, the authors discuss the current evidence of the etiology and management of the various presentations. While it is appreciated that many of these complaints are transient, their impact on the maternal quality of life can be significant, and therefore, medical practitioners should be aware of what to expect in order to provide reassurance to patients and also to safely manage such symptoms.
Data Sources: MEDLINE and EMBASE databases were searched for publications related to otolaryngology and pregnancy.
Review Methods: All literature was searched for and reviewed by 2 authors independently. Search results were then cross-examined, and any differences were settled by consensus.
Results: Pregnancy leads to circulatory changes and increased susceptibility to viral reactivation, and along with the exertion of parturition, it can lead to tinnitus, facial palsies, and deafness. Rising levels of sex hormones and heightened sensitivity to allergens may influence the nasal mucosa, precipitating epistaxis and rhinitis. Increased progesterone and the increased intra-abdominal pressure of the growing fetus can lead to symptoms and sequelae of laryngopharyngeal reflux. Evidence for the treatment of pregnancy-induced symptoms is principally restricted to case reports and retrospective studies.
Conclusion: Recognition and understanding of pregnancy-related ear, nose, and throat complaints will allow otolaryngologists to reassure and manage these patients, improving their experience of the gestational period. High-quality evidence for their management is limited, with further research required.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/0194599811407572 | DOI Listing |
Objective: The ADVOCATE trial demonstrated that treatment of active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) with avacopan was noninferior in achieving remission at week 26 and superior for sustained remission at week 52 compared with a prednisone taper. This analysis of ADVOCATE evaluated the efficacy and safety of avacopan in patients with ear, nose, throat (ENT), or lung manifestations.
Methods: This post hoc analysis included patients enrolled in ADVOCATE with ENT or lung manifestations at baseline.
Immun Inflamm Dis
January 2025
Department of Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania.
Introduction: Allergic rhinitis is the specific inflammation against allergen by immune defense cells on the nasal mucosa, which can lead to chronic nasal symptoms such as sneezing, itching, runny nose, and nasal congestion. It is associated with high morbidity including sinusitis, asthma, otitis media, hypertrophied inferior turbinate, and nasal polyps. Despite its complications, it remains poorly recognized and tracked.
View Article and Find Full Text PDFActa Otolaryngol
December 2024
Department of Otolaryngology Head and Neck Surgery & Audiology and Neurotology, Karolinska University Hospital, Department of Clinical Science, Intervention and Technology, Karolinska Institute, Stockholm, Sweden.
Int J Burns Trauma
December 2024
Department of Plastic Surgery, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine Nanjing, Jiangsu, China.
Mammalian bites to the face challenges not only related to wound healing but also to aesthetic outcomes. This study aims to summarize 7 years of experience in treating mammalian bite wounds and propose a surgical approach for managing these wounds. From July 2016 to August 2023, 185 cases were treated and retrospectively evaluated.
View Article and Find Full Text PDFJ Ophthalmol
January 2025
Department of Ophthalmology, Oslo University Hospital, P.O. Box 4950, Nydalen, Oslo 0424, Norway.
Dry eye disease (DED) is a multifactorial disorder affecting millions worldwide. Inflammation plays a central role in DED. The aim of this review is to critically evaluate the literature concerning the efficacy and safety of lifitegrast, a small molecule immunomodulator that blocks the action of lymphocyte function-associated antigen-1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!